• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $82 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-14 Mln

Vincerx Pharma Inc. (VINC) Share Price

$4.33

As on 01-Mar-2024 16:13 EST

up-down-arrow $0.5815.47%

  • Prev Close info

    $3.75

  • Day's Openinfo

    $3.79

  • Today's Highinfo

    $4.44

  • Today's Lowinfo

    $3.73

  • Today's Volumeinfo

    934,865

  • 52 Week rangeinfo

    $0.61 - 4.44

Please wait...

Vincerx Pharma Inc. (VINC) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Vincerx Pharma (VINC)
266.95 230.53 566.15 273.28 -39.24 -- --
S&P BSE Sensex*
2.17 3.02 9.37 24.23 13.97 15.40 13.33
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 02-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
Vincerx Pharma (VINC)
15.69 -89.99 -51.27
S&P Small-Cap 600
13.89 -17.42 25.27
S&P BSE Sensex
18.74 4.44 21.99

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Vincerx Pharma Inc. (VINC) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Vincerx Pharma Inc. (VINC)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Vincerx Pharma Inc. (VINC)

        Founder, Chairman & CEO

        Dr. Ahmed M. Hamdy M.D.

        Founder, President, COO, Secretary & Director

        Dr. Raquel E. Izumi Ph.D.

        Headquarters

        Palo Alto, CA

        FAQs for Vincerx Pharma Inc. (VINC)

        The total asset value of Vincerx Pharma Inc. (VINC) stood at $ 35 Mln as on 30-Sep-23

        The share price of Vincerx Pharma Inc. (VINC) is $4.33 (NASDAQ) as of 01-Mar-2024 16:13 EST. Vincerx Pharma Inc. (VINC) has given a return of -39.24% in the last 3 years.

        Vincerx Pharma Inc. (VINC) has a market capitalisation of $ 82 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Vincerx Pharma Inc. (VINC) is 5.16 times as on 29-Feb-2024, a 0.73% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Vincerx Pharma Inc. (VINC) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Vincerx Pharma Inc. (VINC) and enter the required number of quantities and click on buy to purchase the shares of Vincerx Pharma Inc. (VINC).

        Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. Address: 260 Sheridan Avenue, Palo Alto, CA, United States, 94306

        The CEO & director of Dr. Ahmed M. Hamdy M.D.. is Vincerx Pharma Inc. (VINC), and CFO & Sr. VP is Dr. Raquel E. Izumi Ph.D..

        The promoters of Vincerx Pharma Inc. (VINC) have pledged 0% of the total equity as on Sep-23.

        Vincerx Pharma Inc. (VINC) Ratios
        Return on equity(%)
        -158.97
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Vincerx Pharma Inc. (VINC) was $-14 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $81.67 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-14.34 Mln
        • Cash date-information $20.80 Mln
        • Total Debt info $2.77 Mln
        • Insider's Holding 23.98%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $0.61 - 4.44
        • Shares outstanding share-outstanding 21,380,600
        • 5 Years Aggregate:

          CFO: $-143.82 Mln

          EBITDA: $-171.67 Mln

          Net Profit: $-132.35 Mln

        About The Company

        • IPO Date 27-May-2020
        • Founder, Chairman & CEO Dr. Ahmed M. Hamdy M.D.
        • Founder, President, COO, Secretary & Director Dr. Raquel E. Izumi Ph.D.
        • Listing key-listing NASDAQ: VINC
        • Country United States
        • Headquarters headquarters Palo Alto, CA
        • Website website https://vincerx.com
        • Business

          Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor...  that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California. Address: 260 Sheridan Avenue, Palo Alto, CA, United States, 94306  Read more

        share-fund-plan-icon